Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways

Journal of Cellular Physiology

Volumn 165, Issue 1, 1995, Pages 107-118

  Schnaper, H William ^a,b   Barnathan, Elliot S ^c   Mazar, Andrew ^d   Maheshwari, Shailendra ^a   Ellis, Stefanie ^a   Cortez, Shirley L ^e   Baricos, William H ^e   Kleinman, Hynda K ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ABBOTT LABORATORIES   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; ENZYME INHIBITOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

CAPILLARIES; CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; GELATINASES; GENE EXPRESSION; HUMAN; IN VITRO; LAMININ; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEOGLYCANS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028820807     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.1041650114     Document Type: Article

References (47)

1. In vivo patterns of expression of urokinase and its inhibitor PAI‐1 suggest a concerted role in regulating physiological angiogenesis
2. Characterization and regulation of the urokinase receptor of human endothelial cells
3. Characteriztion of human endothelial cell urokinase‐type plasminogen activator receptor protein and messenger RNA
4. Interaction of single‐chain urokinase‐type plasminogen activator with human endothelial cells
5. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis
6. Induction of cell migration by pro‐urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells
7. On the regulation and control of fibrinolysis
8. Seeding of intravascular stents with genetically engineered endothelial cells
9. Plasminogen activatin by receptor‐bound urokinase
10. Characterization of the cellular binding site for urokinase‐type plasminogen activator
11. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI‐1 is an immunocytochemical marker of invading trophoblasts
12. Various rat adult tissues express only one major RNA species from the glyceraldehyde‐3‐phosphate‐dehydrogenase multigene family
13. Two different domains of laminin mediate the differentiation of human endothelial cells into capillary‐like structures in vitro
14. Plasminogen activator and collagenase production by cultured capillary endothelial cells
15. Human protease nexin‐1. Further characterization using a highly specific polyclonal antibody
16. Proteolytic processing of the 72,000‐Da type IV collagenase by urokinase plasminogen activator
17. Basement membrane complexes with biological activity
18. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue‐type and urokinase‐type plasminogen activators
19. Cleavage of laminin by thrombin and plasmin: Alpha thrombin selectively cleaves the beta chain of laminin
20. Effects of soluble factors and extracellular matrix components on vascular cell behavior in vitro and in vivo: Models of deendothelialization and repair
21. Domain analysis of urokinase plasminogen activator (u‐PA): Preparation and characterization of intact A‐chain molecules
22. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor‐induced proteinases
23. Purification and characterization of a two‐chain inhibitor of metalloproteinases (TIMP) type 2 and a low molecular‐weight TIMP‐like protein
24. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
25. Estrogens promote angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model
26. Identification of an inhibitor of neovascularization from cartilage
27. Characterization of recombinant human single chain urokinase‐type plasminogen activator mutants produced by site‐specific mutagenesis of lysine 158
28. Protein kinase C in tumor necrosis factor induction of endothelial cell urokinase‐type plasminogen activator
29. Urokinase‐type plasminogen activator mediates fibroblast growth factor‐mediated bovine endothelial cell migration independent of its proteolytic activity
30. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteases
31. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma
32. Upregulation of urokinase receptor expression on migrating endothelial cells
33. Structural requirements for the growth factor activity of the amino‐terminal domain of urokinase
34. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis
35. Proteoglycans as modulators of growth factor activities
36. Release of basic fibroblast growth factor‐heparan sulfate complexes from endothelial cells by plasminogen activator‐mediated proteolytic activity
37. Indespensable role of tissue‐type plasminogen activator in growth factor‐dependent tube formation of human microvascular endothelial cells in vitro
38. Regulation of cell function by extracellular matrix
39. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro
40. Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain
41. Plasma membrane‐dependent activation of the 72‐kDa type IV collagenase is prevented by complex formation with TIMP‐2
42. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells
43. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components
44. Cytokines induce urokinase‐dependent adhesion of human myeloid cells. A regulatory role for plsminogen activator inhibitors
45. Endothelial turnover
46. A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro method
47. cDNA cloning and expression in Escheria coli of a plasminogen activator from human placenta